Sectoral Asset Management Inc. Buys 180 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Sectoral Asset Management Inc. lifted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report) by 4.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,094 shares of the specialty pharmaceutical company’s stock after purchasing an additional 180 shares during the quarter. Sectoral Asset Management Inc.’s holdings in Jazz Pharmaceuticals were worth $504,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in JAZZ. Armistice Capital LLC boosted its holdings in shares of Jazz Pharmaceuticals by 108.4% in the 4th quarter. Armistice Capital LLC now owns 651,626 shares of the specialty pharmaceutical company’s stock worth $80,150,000 after purchasing an additional 338,882 shares in the last quarter. Pacer Advisors Inc. raised its position in Jazz Pharmaceuticals by 28.1% during the 4th quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company’s stock valued at $125,916,000 after purchasing an additional 224,865 shares during the last quarter. Aristotle Capital Management LLC bought a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $22,748,000. Baupost Group LLC MA raised its position in shares of Jazz Pharmaceuticals by 23.7% in the 4th quarter. Baupost Group LLC MA now owns 833,696 shares of the specialty pharmaceutical company’s stock worth $102,545,000 after acquiring an additional 160,000 shares in the last quarter. Finally, KBC Group NV raised its position in shares of Jazz Pharmaceuticals by 2,191.4% in the 4th quarter. KBC Group NV now owns 163,858 shares of the specialty pharmaceutical company’s stock worth $20,155,000 after acquiring an additional 156,707 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock traded up $5.73 during trading on Friday, reaching $112.05. The company had a trading volume of 1,038,198 shares, compared to its average volume of 870,878. Jazz Pharmaceuticals plc has a 52 week low of $103.01 and a 52 week high of $146.70. The firm’s 50-day simple moving average is $109.90 and its 200 day simple moving average is $117.76. The firm has a market capitalization of $7.06 billion, a price-to-earnings ratio of 23.10, a price-to-earnings-growth ratio of 1.63 and a beta of 0.62. The company has a current ratio of 2.27, a quick ratio of 1.90 and a debt-to-equity ratio of 1.38.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) last announced its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 EPS for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. The company had revenue of $901.98 million during the quarter, compared to the consensus estimate of $938.99 million. Sell-side analysts forecast that Jazz Pharmaceuticals plc will post 15.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on JAZZ shares. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, May 31st. Needham & Company LLC reaffirmed a “buy” rating and set a $222.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, May 2nd. Royal Bank of Canada reiterated an “outperform” rating and set a $195.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, February 29th. Stifel Nicolaus increased their target price on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Finally, UBS Group cut their target price on Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating on the stock in a research note on Friday, March 1st. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $190.92.

Check Out Our Latest Stock Report on Jazz Pharmaceuticals

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of the firm’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $109.65, for a total transaction of $548,250.00. Following the sale, the executive vice president now directly owns 36,629 shares of the company’s stock, valued at $4,016,369.85. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.40% of the stock is owned by insiders.

Jazz Pharmaceuticals Profile

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Featured Articles

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.